Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma

ClinicalTrials.gov ID: NCT00027716

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00027716. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Institutional, Open-Label, Two-Group, Phase II Study of PS-341 (LDP-341, NSC #681239) in Patients With Advanced or Metastatic Sarcoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have advanced or metastatic sarcoma.

Study identification

NCT ID: NCT00027716
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Enrollment: Not listed

Conditions and interventions

Conditions

Sarcoma

Interventions

bortezomib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2001 (Type not available)
Primary completion: May 2004 (Actual)
Completion: May 2004 (Actual)
Last update posted: Jun 6, 2013

2001 – 2004

United States locations

U.S. sites: 6
U.S. states: 4
U.S. cities: 5

Facility	City	State	ZIP	Site status
University of Colorado Cancer Center at University of Colorado Health Sciences Center	Aurora	Colorado	80010	—
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute	Boston	Massachusetts	02115	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10021	—
University of Chicago Cancer Research Center	New York	New York	10021	—
Albert Einstein College of Medicine	The Bronx	New York	10461	—
Abramson Cancer Center at University of Pennsylvania Medical Center	Philadelphia	Pennsylvania	19104-4283	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00027716, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 6, 2013 · Synced Nov 13, 2026